You are here

Positive Phase II Results for Anti-Interleukin Nanobody ALX-0061 in Rheumatoid Arthritis

Up to 63% of patients achieved disease remission (Feb. 13)

Positive efficacy and safety data have been reported from the phase II part of a combined phase I/II study of the anti–interleukin-6 receptor (anti-IL-6R) nanobody ALX-0061 (Ablynx) in patients with moderately to severely active rheumatoid arthritis (RA) on a stable background of methotrexate.

In this phase II analysis, 37 patients with RA were randomly assigned to three groups of intravenously administered ALX-0061 (1 mg/kg every 4 weeks, 3 mg/kg every 4 weeks, or 6 mg/kg every 8 weeks) or placebo. A total of 34 patients were evaluable for efficacy at the 12-week interim period, and all of these patients continued treatment until week 24.

Depending on the patient’s disease status at week 10, the monthly dose was increased (from 1 mg/kg to 3 mg/kg, or from 3 mg/kg to 6 mg/kg) or the dosing regimen was intensified (from 6 mg/kg every 8 weeks to 6 mg/kg every 4 weeks), and patients receiving placebo could start monthly ALX-0061 treatment at 3 mg/kg. Twenty-four patients (86%) completed the study on their ALX-0061 starting regimen (the “unmodified” group); the dosing regimen was modified for four patients (the “modified” group); and three patients were switched from placebo to ALX-0061 (the “switchers” group).

The American College of Rheumatology (ACR) criteria for 20%, 50%, and 70% improvement (ACR20, ACR50, and ACR70) were achieved in 83%, 71%, and 58% of the pooled “unmodified” group, respectively. The corresponding ACR rates in the pooled “modified” group were 75%, 50%, and 50%. The pooled “switchers” group showed rates of 100%, 67%, and 0%.

DAS28 is an RA disease activity score based on C-reactive protein (CRP), tender and swollen joint counts of 28 defined joints, and the physician’s global health assessment. DAS28 remission was achieved by 63% of the pooled “unmodified” group, by 50% of the pooled “modified” group, and by 33% of the pooled “switchers” group.

At all doses tested, ALX-0061 was well-tolerated. No clinically relevant neutropenia or clinically significant increases in lipid levels (cholesterol and triglycerides) were observed, and there were no serious infections.

ALX-0061 targets the interleukin 6 pathway via its IL-6 receptor (IL-6R), which plays a key role in the inflammation process in RA. The drug can be administered both intravenously and subcutaneously.

Source: Ablynx; February 13, 2013.

Recent Headlines

Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology
Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival